Skip to content

Arvinas ARVN Book value per share

Book value per share at other companies

Nurix Therapeutics, Inc. logo
Nurix Therapeutics, Inc.NRIX
$4.37-24.1%
Kymera Therapeutics logo
Kymera TherapeuticsKYMR
$15.79+60.9%
Monte Rosa Therapeutics, Inc. logo
Monte Rosa Therapeutics, Inc.GLUE
$5.23+57.5%
Relmada Therapeutics, Inc. logo
Relmada Therapeutics, Inc.RLMD
$2.53+242%
Nuvectis Pharma, Inc. logo
Nuvectis Pharma, Inc.NVCT
$0.61-42.2%
ArriVent BioPharma, Inc. logo
ArriVent BioPharma, Inc.AVBP
$7.19+20.3%

Other financials

Income statement

See full
Revenue$15.6M-91.7%
Operating income-$63.8M-189%
Net income-$57.6M-169%
EPS (diluted)-$0.90-179%

Balance sheet

See full
Cash & equivalents$87.3M+7.8%
Total debt$8.6M-19.6%
Total equity$386.8M-41.4%
Total assets$647.5M-35.3%

Cash flow

See full
Operating cash flow-$69.2M+22.2%
CapEx$1.3M+225%
Free cash flow-$70.5M+21.1%

Valuation

See full
Market cap$518.11M-4.6%
Enterprise value$439.41M-7.1%
P/S5.8×+4.5×

Profitability

See full
Operating margin-283.8%-310pp
Net margin-247.5%-260pp
FCF margin-287.4%

Returns & leverage

See full
Return on equity-42.3%-53.5pp
Debt / equity0.0×
Current ratio5.4×+0.9×

Where this comes from

Calculated from Arvinas’s reported figures.

Based on the most recent quarter.

The official record: Arvinas’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Arvinas's book value per share.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Arvinas's book value per share?
Arvinas (ARVN) reported book value per share of $6.04 in Q1 2026.
How has Arvinas's book value per share changed year-over-year?
Arvinas's book value per share decreased by 33.4% year-over-year, from $9.08 to $6.04.
What is the long-term trend for Arvinas's book value per share?
Over 5 years (2020 to 2025), Arvinas's book value per share has grown at a -17.8% compound annual growth rate (CAGR), from $16.26 to $6.12.
What does book value per share mean?
Shareholders' equity divided by diluted shares outstanding at the quarter end. The accounting (book) value attributable to each share.